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Abstract
Background: The bovine spongiform encephalopathy (BSE) epidemic and the emergence of a new
human variant of Creutzfeldt-Jakob Disease (vCJD) have led to profound changes in the production
and trade of agricultural goods. The rapid tests currently approved for BSE monitoring in
slaughtered cattle are all based on the detection of the disease related isoform of the prion protein,
PrPd, in brain tissue and consequently are only suitable for post-mortem diagnosis. Objectives: In
instances such as assessing the health of breeding stock for export purposes where post-mortem
testing is not an option, there is a demand for an ante-mortem test based on a matrix or body fluid
that would permit easy access and repeated sampling. Urine and urine based analyses would meet
these requirements.
Results:  Two dimensional differential gel eletrophoresis (2D-DIGE) and mass spectrometry
analyses were used to identify proteins exhibiting differential abundance in the urine of BSE infected
cattle and age matched controls over the course of the disease. Multivariate analyses of protein
expression data identified a single protein able to discriminate, with 100% accuracy, control from
infected samples. In addition, a subset of proteins were able to predict with 85% ± 13.2 accuracy
the time post infection that the samples were collected.
Conclusion: These results suggest that in principle it is possible to identify biomarkers in urine
useful in the diagnosis, prognosis and monitoring of disease progression of transmissible spongiform
encephalopathy diseases (TSEs).
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Background
Bovine Spongiform Encephalopathy (BSE) was first
described in the UK in 1985 and became an epidemic that
peaked with 37, 280 cases reported in 1992[1]. BSE and
other Transmissible Spongiform Encephalopathy (TSE)
diseases are untreatable, uniformly fatal degenerative syn-
dromes of the central nervous system (CNS). A post-mor-
tem examination revealing characteristic deposits of an
insoluble host encoded protein, astrocytosis and spongio-
sis is required for definitive diagnosis. The characteristic
protein deposits are formed by the accumulation of mis-
folded isoforms of a host-encoded protein, PrPc, or prion
protein. The disease associated isoforms are derived from
the host protein, PrPc, by a posttranslational process and
are often distinguished by their partial resistance to pro-
teinase K digestion[2]. The term PrPd is used to denote the
presence of abnormal accumulations or isoforms of PrP
detected by any method without prejudice as to its bio-
chemical properties, its infectivity, source or host
range[3].
The new human variant of Creutzfeldt-Jakob Disease
(vCJD) identified in 1996 is thought to have been caused
by dietary exposure to BSE infected products[4]. In con-
trast to typical cases of classical CJD, vCJD seems to affect
predominantly young adults. Risk reduction measures
implemented in response to BSE and the emergence of
this new disease led to profound changes in the produc-
tion and trade of agricultural goods. To minimize the risk
of disease transmission to consumers specified risk mate-
rials (SRM), constituting tissues known to harbour high
levels of infectivity such as the brain and spinal cord, have
been removed from the food chain. In addition, the test-
ing of risk animals and of all slaughtered animals above
the age of thirty months for BSE is a requisite for access to
many potential markets for beef products. The rapid tests
currently approved for BSE monitoring in slaughtered cat-
tle are all based on the detection of the disease related iso-
form of the prion protein, PrPd, in brain tissue and
consequently are only suitable for post-mortem diagno-
sis.
A reliable ante-mortem test would provide an alternative
to the routine culling of herds when a confirmed case of
BSE is detected. More importantly, in instances such as
assessing the health of breeding stock where post-mortem
testing is not an option, there is a demand for ante-mor-
tem tests based on a matrix or body fluid that would per-
mit repeated sampling. The development of such assays,
based on the detection of PrPd, have been complicated by
the extremely low amounts of PrPd present in accessible
tissues, or in body fluids such as cerebrospinal fluid
(CSF), blood and urine [5-8]. Furthermore, the demon-
stration that most infectivity is associated with protease
sensitive forms of PrPd also calls into question the reliabil-
ity of tests reliant on the association of prion infectivity
with the presence of a proteinase K resistant fragment that
is measured by Western blotting, enzyme-linked immu-
nosorbent assay, or immunohistochemistry[9].
The advent of the protein misfolding cyclic amplification
assay (PMCA), offered a possible solution to this prob-
lem[10]. Indeed, the use of modified PMCA assays using
relatively defined components has resulted in the detec-
tion of PrPd in the CSF, serum and urine of terminal stage
hamsters. However, PMCA based methods require further
investigation and validation before they are ready for rou-
tine use [11-15]. Thus, the identification of alternative
biomarkers in accessible tissues or body fluids applicable
to the development of diagnostic tests remains a relevant
approach.
Urine, due to its ease of collection and comparatively less
complex protein profile, is perhaps the ideal matrix for
surveillance provided a sufficiently sensitive and specific
alternative biomarker for disease can be identified. Previ-
ously, it was demonstrated that the presence of protease
resistant light chain immunoglobulin in urine may consti-
tute a surrogate marker for prion diseases[6,16]. Building
on these results we have used two dimensional differen-
tial gel electrophoresis (2D-DIGE) and mass spectrometry
analyses to demonstrate that the relative abundance of
other proteins in the urine of BSE infected cattle and age
matched controls change over the course of the disease.
These analyses, performed on biological replicates, identi-
fied a single protein able to discriminate between control
and infected cattle throughout the course of the disease as
well as a subset of proteins able to accurately identify the
collection date of the samples. The results indicate that
biomarkers in urine may be useful in the diagnosis, prog-
nosis and monitoring of disease progression of transmis-
sible spongiform encephalopathy diseases (TSEs).
Methods
Urine
Urine was collected from 4 Simmental cross-breed calves
that were orally infected with BSE and 4 age matched con-
trols at 8 month intervals throughout the course of the
disease. The calves were infected at 4 months of age. All
cattle were scored every second month for clinical signs.
BSE was confirmed by immunohistochemistry of the
obex[17]. Urine samples were frozen immediately after
collection and stored at -80°C until processing. This gen-
erated 4 infected and 4 control biological replicates at
each of the 6 time points. One sample from this set was
not obtained resulting in 47 samples in total.
Urine samples (80–90 mL) were thawed overnight at 4°C.
Insoluble particles were removed by a pre-spin, 4°C at
415 g for 5 minutes. The soluble fraction was concen-Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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trated with a 5 K MWCO Centricon Plus-70 centrifugal fil-
ter unit (Millipore) in a swinging bucket rotor at 4°C and
3400 g for approximately 20 minutes or until volumes
reached less than 4 mL. The urine was further concen-
trated with an Amicon 4 ml 5 K MWCO centrifugal filter
unit (Millipore) at 4°C and 7000 g until volumes reached
200 μl.
The concentrated urine samples were purified using a 2D
Clean Up kit (GE Healthcare) according to the manufac-
turer's recommendations. The resulting protein pellets
were resuspended in 100 μL of Rehydration Buffer (0.03
M Tris, 8 M Urea, 2 M Thiourea, 2% Chaps, pH 8.5). Sam-
ples were adjusted to pH8.5 with the addition of 1–5 μl of
0.05 M NaOH. The concentration of each sample was
determined using a 2D Quant kit (GE Healthcare) accord-
ing to the manufacturer's recommendations. The pooled
internal standard was created by combining 100 μg of
each sample.
2D Gel Electrophoresis
CyDye™ (GE Healthcare) minimal labeling was per-
formed as per the manufacturer's recommendations (400
pmol: 50 μg) with the Cy2 label reserved for the pooled
sample. The control and infected samples were labeled in
a randomized manner with either Cy3 or Cy5. An equal
volume of 2× Rehydration Buffer (0.03 M Tris, 8 M Urea,
2 M Thiourea, 2% Chaps, pH 8.5, 4 mg/ml Dithiothreitol
(DTT), 1% IPG buffer pH 4–7) was added to a mixture
comprised of 30 μg each of the labeled Pooled, Control
and Infected samples. After a 10 minute incubation on ice
approximately 400 μl of 1× Rehydration Buffer (0.03 M
Tris, 8 M Urea, 2 M Thiourea, 2% Chaps, pH 8.5, 2 mg/ml
DTT, 0.5% IPG buffer pH 4–7) and 5 μl of 1% Bromophe-
nol blue (10 mM TrisCl pH 8.5) were added to bring the
volume up to a total of 450 μl. The labelled samples were
loaded onto a reswelling tray and overlaid with a 24 cm
Immobiline DryStrip pH 4–7 (GE Healthcare) and DryS-
trip Cover Fluid and allowed to rehydrate overnight at
room temperature. The strip was transferred to a Manifold
filled with 108 mL of DryStrip Cover Fluid and placed on
an Ettan IPGphor3 focusing apparatus that was pro-
grammed as follows: Step 30 V 8 hrs, Step 500 V 1 hr, Step
1000 V 1 hr, Grad 10000 V 3 hrs and Step 10000 V 3 hrs.
A final focusing program: Grad 10000 V 0:20 hr and Step
10000 V until the volt hours reached a total of 55000 was
added as required.
Completed isoelectric focusing (IEF) runs were stored at -
80°C until the second dimension was run. IEF strips were
prepared for second dimension gels by incubating in two
different Equilibration Buffer solutions (50 mM Tris-Cl
pH8.8, 6 M Urea, 30% Glycerol, 2% SDS, 0.2%
Bromophenol Blue, supplemented with either 65 mM
DTT – 1st incubation or 135 mM Iodoacetamide – 2nd
incubation) for 15 minutes each with gentle rocking.
The prepared IEF strips were placed on 15–20% gradient
gels between low fluorescent glass plates (NextGen Sci-
ences). After sealing in place with a 1% agarose solution,
the gels were placed in the Ettan DALT6 unit (GE Health-
care) and run at 2 W overnight and then at 100 W until a
total of 3100 Vhr was reached.
Data Acquisition and Analysis
Two randomly selected samples labeled with Cy5 and Cy3
were co-resolved with a Cy2 labeled pooled internal
standard on each of 24 gels. Gels were scanned within 24
hours of being run on a Molecular Dynamics Typhoon
9400. Gel images were cropped using Molecular Dynam-
ics Image Quant 5.2 software.
Upon visual inspection of the 24 gels, proteins on three
gels were observed to not be well resolved. These three
gels were immediately rerun using the same Cy2 labelled
standard to obtain gel images suitable for analysis.
Acquired gel images were first analyzed in the DeCyder™
Differential In-gel Analysis (DIA) module of the GE
HealthCare DeCyder™ 2D Software version 6.5. The DIA
generated identical spot feature detection patterns on all
images derived from the same gel. This ensured that the
internal standard and the sample spot features had identi-
cal spot boundaries. Quantification of spot features was
achieved by normalizing spot feature volumes against the
internal standard.
The DIA files were imported into the Biological Variation
Analysis (BVA) module to match spot feature migration
patterns and normalize abundance values using the
unique signal of each spot feature from the pooled inter-
nal standard. The standardized abundance was derived
from the normalized spot volume, standardized against
the intra gel standard. To obtain a normal distribution
around zero the spot feature standardized log abundance
values were used for inter-gel spot comparisons.
Multivariate analysis was performed in the DeCyder™
Extended Data Analysis (EDA) module version 1.0.
Marker selection and classifier creation were performed
using partial least squares for the searching and ranking of
spot features and K-nearest neighbor (KNN) to evaluate
the spot feature set found.
Protein Digest
Spot features of interest were manually excised using a
Gilson P1000 Pipetman from SYPRO Ruby stained pre-
parative gels and stored in 1% acetic acid. The ART pipet
tips were cut with a razor blade to increase the pore size.
The gel slices were washed a total of five times; first withProteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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sterile water, secondly with 25 mM ammonium bicarbo-
nate and finally three consecutive washes with 25 mM
ammonium bicarbonate/50% acetonitrile solution with
the last wash being an overnight incubation at 10°C. Gel
slices were dehydrated with 100% acetonitrile before add-
ing trypsin (Trypsin Gold, Promega) at 20 μg/ml (in 40
mM ammonium biocarbonate/10% acetonitrile solution)
and incubated at 37°C overnight. Tryptic peptides were
extracted from the gel slices by washing with 0.1% formic
acid and then 0.1% formic acid/50% acetonitrile solu-
tions. The tryptic peptide extracts were vacuum-dried and
reconstituted with 10 μl of 5% acetonitrile and 0.1% for-
mic acid.
LC/MS/MS
Nanoflow LC of tryptic peptide samples was performed
with an Agilent 1100 nanoflow LC system equipped with
a C18 pre-column (Zorbax 300SB-C18, 5 μm, 5 mm × 0.3
mm, Agilent) and a C18 analytical column (Zorbax 300SB-
C18, 3.5 μm, 15 cm × 75 μm, Agilent). The aqueous
mobile phase (solution A) contained 5% acetonitrile and
0.1% formic acid, and the organic mobile phase (solution
B) contained 95% acetonitrile and 0.1% formic acid. Sam-
ples (5-μl injected) were loaded and washed on the pre-
column for 5 minutes with solution A at 50 μl/min. Pep-
tides were then eluted off the pre-column and through the
analytical column with a 50 minute profile at 300 nl/min:
1 to 30% solution B over 30 min, 40% to 95% B over 5
minutes, 95% B over 5 minutes, and re-equilibrated for 10
minutes at initial conditions. Peptides were eluted directly
into a QStar XL via a nanospray ion source (Applied Bio-
systems). The ion source was equipped with a 50-μm
inner-diameter, fuse-silica needle with a 15-μm tip (Pico-
Tip Emitter, New Objective). Data dependant acquisition
was performed with a 10 second cycle: 1-second interval
for acquiring intact peptide signal (MS), and three 3-sec-
ond intervals for collision induced dissociation of the 3
most intense peptide signals in the initial 1-second inter-
val (MS/MS). The MS m/z range was 350 to 1500, and the
MS/MS m/z range was 70 to 2000. Collision energy was
automatically determined by the data acquisition soft-
ware (Analyst QS 1.1). MS/MS data were acquired for the
entire LC run.
Data analysis
Mascot (version 2.2, Matrix Science) search engine was
used to search the NCBI database with the MS/MS data.
The search parameters were as follows: taxonomy was
unrestricted, protein molecular weight was unrestricted,
fixed modification was Carbamidomethyl (C), variable
modification was Oxidation (M), peptide and fragment
mass tolerance was ± 0.3 Da, and up to one missed cleav-
age was allowed. Individual ion scores > 54 indicate iden-
tity or extensive homology (p < 0.05).
Results
Gel image acquisition
Urine was collected from 4 Simmental cattle orally
infected with BSE and 4 age matched controls at 8 month
intervals over the first 40 months of the disease. This gen-
erated 4 infected and 4 control biological replicates at
each of the 6 time points. An internal gel standard was cre-
ated by pooling equivalent amounts of protein from each
sample. In total 27 gels, each comprised of the internal
standard and two biological samples, were run to obtain
gel images suitable for analysis. Ultimately, 46 gel images
representing 46 biological samples and 24 gel images of
the internal standard were used for analyses (Table 1).
The acquired gel images were analyzed using the DeCy-
der™ DIA and BVA software modules. Manual landmark-
ing of 12 spot features across 24 gel images of the internal
standard was performed in order to improve the accuracy
of the gel-to-gel matching process. This resulted in the
detection, quantification, and matching of 1329 master
spot features across the 24 gels, all containing the same
internal standard (Figure 1).
PCA analyses
Multivariate analyses of protein expression data derived
from the BVA were performed using the DeCyder™
Extended Data Analysis Software (EDA). The gel images
were first grouped such that the 6 samples from each indi-
vidual animal formed a group. This resulted in 8 groups
each representing one of 8 biological replicates. The data
were filtered so that only the 36 spot features exhibiting
statistically significant (ANOVA p < 0.01) changes in
abundance and present on all 46 gel images were consid-
ered in the following analyses.
Principle component analysis (PCA) on this filtered data
set was performed to identify the relative contributions of
the inherent differences between individuals and disease
state on the variance exhibited by the 8 biological repli-
cates. The PCA analysis demonstrated that the cows gener-
ally segregated into infected and control groups indicating
that the disease status of the animals was the primary fac-
tor affecting the differential abundance of urinary proteins
(Figure 2). The exception was cow #54. At no time point
did this animal cluster with the other infected animals
and it further diverged from all other animals as the dis-
ease progressed.
The reason for the atypical pattern demonstrated by this
animal is not known, but it is interesting to note that it
had an atypical phenotype as well. Cow #54 developed
clinical signs, as determined by regular scoring for clinical
signs (20 minutes/animal), between 40–46 months post
infection (mpi), but then phenotypically recovered before
reaching the terminal stage of the disease at 56 mpi. InProteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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contrast, cows #38 and #53 reached the terminal stage of
the disease at 44 mpi and cow #40 at 48 mpi. The behav-
iour of cow #54 was atypical, not only with respect to the
other three infected cattle considered in this study, but
from the other 10 infected cows in the herd that were
allowed to reach the terminal stage of the disease. For the
purposes of this experiment all the data representing this
animal were excluded from subsequent analyses. BSE
infection was confirmed in all four cases by immunohis-
tochemical analyses of the obex.
The 40 remaining gel images were then grouped according
to disease state and months post infection. Control and
infected cows at each time point formed a group. This
resulted in 10 groups each representing either the 3
remaining infected cows or the 4 control cows at a partic-
ular point in the experiment. Samples collected from
these 7 cows prior to the start of the experiment formed an
11th group (normal). The data were again filtered reveal-
ing 56 spot features that exhibited statistically significant
(ANOVA p < 0.01) changes in abundance and were
present on all 40 gel images for consideration in the fol-
lowing analyses.
PCA analysis on this filtered data set was performed to
identify the relative contributions of time and disease
state on the variance observed (Figure 3). The cows again
segregated into infected and control groups further indi-
cating that the disease status of the animals was the pri-
mary cause of the differential abundance in urinary
proteins observed. Nonetheless, within the infected group
it was also observed that the individual time points clus-
tered together and generally moved down and to the right
as disease progressed. A somewhat similar, but less pro-
nounced pattern was observed in the control samples.
This indicates that time did factor into the differential
abundance of urinary proteins observed. That time played
a role in the urinary protein profile was reinforced by the
observation that the animals at 0 mpi formed a distinct
group (normal).
Table 1: Sample loading and labelling matrix.
group cow gel no. dye mpi group cow gel no. dye mpi
infected 38 na na 0 control 67 23 Cy3 0
infected 40 1 Cy5 0 control 69 22 Cy5 0
infected 53 15 Cy3 0 control 72 11 Cy5 0
infected 54 17 Cy5 0 control 73 13 Cy3 0
infected 38 24 Cy3 8 control 67 1 Cy3 8
infected 40 8 Cy3 8 control 69 3 Cy5 8
infected 53 13 Cy5 8 control 72 23 Cy5 8
infected 54 8 Cy5 8 control 73 9 Cy3 8
infected 38 19 Cy5 16 control 67 24 Cy5 16
infected 40 27 Cy3 16 control 69 14 Cy3 16
infected 53 25 Cy3 16 control 72 16 Cy5 16
infected 54 18 Cy3 16 control 73 6 Cy5 16
infected 38 19 Cy3 24 control 67 15 Cy5 24
infected 40 21 Cy3 24 control 69 17 Cy3 24
infected 53 na na 24 control 72 3 Cy3 24
infected 54 26 Cy5 24 control 73 21 Cy5 24
infected 38 10 Cy5 32 control 67 14 Cy5 32
infected 40 12 Cy3 32 control 69 9 Cy5 32
infected 53 25 Cy5 32 control 72 2 Cy5 32
infected 54 6 Cy3 32 control 73 16 Cy3 32
infected 38 10 Cy3 40 control 67 20 Cy3 40
infected 40 11 Cy3 40 control 69 2 Cy3 40
infected 53 18 Cy5 40 control 72 26 Cy3 40
infected 54 12 Cy5 40 control 73 27 Cy5 40
The disease state, cow identity and months post infection (mpi) identify the sample. Dyes and gels were randomly assigned to the 4 biological 
replicates of infected and control cows to minimize the influence of dye bias and gel to gel variation. The 2 infected samples marked NA were either 
not collected (cow 52, 24 mpi) or no suitable gel image was obtained (cow 38, 0 mpi)Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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Representative Cy2-labelled internal standard proteome gel image illustrating proteins resolved in the pH4-7 range Figure 1
Representative Cy2-labelled internal standard proteome gel image illustrating proteins resolved in the pH4-7 
range. The gel image as loaded into the DIA module prior to spot detection (A). In panel B the 1329 spot features, including 
spots at the edges of the gel that were outside the pH range of the 1st dimension separation, are each denoted by a green dot. 
The position of the 16 spot features used in the class prediction classifier have been marked with yellow and the associated 
master gel spot feature number assigned to the same spot features on all gels by the DeCyder BVA module are shown.Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
Page 7 of 14
(page number not for citation purposes)
PCA of the 56 spot features that exhibited statistically sig-
nificant (ANOVA p < 0.01) changes in abundance and
were present on all 40 gels revealed 3 outliers representing
either mismatched features or strongly differentially
abundant features (Figure 4A). Visual inspections of all
potential outliers were made in the corresponding BVA
file containing the gel images. The 3 spot features clearly
observed in the infected image were not visible in the con-
trol image of the gel (Figure 4B). Visualization of the
shape of the peak representing spot feature 405 and those
in the surrounding area demonstrated that the matches
were legitimate (Figure 4C). The increase in abundance of
405 ranged from 17 to 77 fold over the course of the
experiment. Graphical representation of the standardized
log abundance obtained for the spot feature 405 demon-
strated strong differential abundance of the spot feature
throughout the experiment. Note the segregation of the
control and infected biological replicates at each time
point (Figure 4D).
Classifier creation
In order to determine whether the differences suggested
by the PCA analyses were sufficient to discriminate con-
trol from infected animals the marker selection and classi-
fier creation functions of the EDA module were used.
Initially this was performed on the pooled data obtained
from all control, infected and normal samples. The data,
as before, were filtered so that only spot features exhibit-
ing statistically significant (ANOVA p < 0.01) changes in
Principle component analysis of the 8 biological replicates Figure 2
Principle component analysis of the 8 biological replicates. The samples obtained from individual infected and control 
cows clustered together indicating that disease is the factor that most influences the differential abundance observed in the 
urine samples. The time of the 6 sample collections from cow #54 are given to illustrate that the urine proteome of this animal 
diverged further from all the other animals as the disease progressed. This analysis was based on the 36 spot features exhibiting 
statistically significant (ANOVA p < 0.01) changes in abundance and present on all 46 gel images. (PC1 = 36.3, PC2 = 15.2).Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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abundance and present on all 40 gel images were consid-
ered.
The partial least squares method was used for the search-
ing and ranking of spot features and K-nearest neighbor
(KNN) was used to evaluate the set of biomarkers found.
The use of 16 biomarkers and KNN classification demon-
strated that the training data set could be classified with
83.3% ± 18.3 accuracy (Table 2). Removal of the con-
founding normal samples led to the identification of a
single spot feature (405) that could discriminate between
the remaining control and infected sample sets with 100%
accuracy.
In order to evaluate the information concerning disease
progression contained in the urine samples the 14 gel
images of the infected samples were considered sepa-
rately. The data were filtered so that only the 25 spot fea-
tures exhibiting statistically significant (ANOVA p < 0.01)
changes in abundance and present on all 14 gel images
were considered. The classifier created using the 16 spot
features identified by marker selection was able to classify
the time post infection that the infected samples were col-
lected with 85% ± 13.2 accuracy. The two misclassified
samples were placed into the immediately proceeding
time point (Table 3).
Principle component analysis of different disease states followed throughout the disease progression Figure 3
Principle component analysis of different disease states followed throughout the disease progression. Ellipses 
have been drawn to illustrate the clustering of the 3 groups (BSE infected, control and normal). Within the infected group it 
can also be seen that the individual time points cluster together. A somewhat similar but less pronounced pattern is observed 
in the control samples. This analysis is based on the 56 spot features exhibiting statistically significant (ANOVA p < 0.01) 
changes in abundance and present on all 40 gel images. (PC1 = 38.6, PC2 = 23.0).Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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In order to parse out those changes due to disease progres-
sion from those associated with aging a similar analysis
was performed on the control samples. The classifier cre-
ated using 16 of the spot features identified by marker
selection was able to classify with 85% ± 19.1 accuracy the
time post infection that the control samples were col-
lected (Table 4). Two of the three misclassified samples
were placed into the immediately proceeding time point.
The 16 spot features used by the 3 classifiers are provided
in Table 5. The rank assigned to the spot features denotes
the relative contribution of each protein to the classifica-
tion. The standardized abundance ratio of the top three
ranked proteins in the disease progression classifier were
plotted with respect to time post infection (Figure 5). The
steady increase or decrease in abundance observed over
the course of the experiment illustrated the utility of the
relative abundance of the spot features in classifying the
urine samples with respect to date post infection. Three of
the spot features utilized to predict disease progression
(597, 1022, 1041) were also used in disease class predic-
tion indicating that these markers are disease specific.
Another disease progression spot feature (710) also
appeared among the control progression markers indicat-
ing that changes in the abundance of this spot feature
were age related.
Differentially abundant spot features Figure 4
Differentially abundant spot features. Principle component analysis of 56 spot features that exhibited statistically signifi-
cant (ANOVA p < 0.01) changes in abundance and were present on all 40 gels (A). The red rectangle on the gel image shows 
the region on the gels where the potential outliers were situated. Two magnified views of this region showing infected and 
control images (B). 3D images of spot feature 405 showing the 23.68 fold increase in abundance observed at 8 mpi (C). Graph-
ical representation of the standardized log abundance data obtained for spot feature 405 (D).Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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LC/MS/MS analyses
The 16 biomarkers making up the class prediction classi-
fier (Figure 1B), designed to discriminate between con-
trol, infected and normal samples, were excised from a
preparative gel and subjected to protein identification
using mass spectrometry and database interrogation as
described in Materials and Methods. MS analysis identi-
fied 5 unique proteins, not including redundancies likely
due to post-translational modifications or proteolysis,
and enabled proteins to be assigned to 13 of the 16 spot
features. A summary of the results of this analysis are
shown in Table 6. See Additional File 1 for additional pro-
tein statistics.
The 5 different proteins representing the 13 spot features
were: clusterin, Ig Gamma-2 chain C region, similar to
GCAP-11/uroguanylin, cystatin E/M, and cathelicidin1.
Some of the redundancies appeared to be due to post-
translational modifications that created charge-related
isoforms that had different iso-electric points, but indis-
tinguishable molecular masses. For example, 2 spot fea-
tures identified as clusterin (393, 405), appeared to meet
this criteria (Figure 4B). It is also interesting to note that
the differential abundance of one of the isoforms is much
more robust than the other (Figure 4A).
Discussion
Recent advances in 2-dimensional gel electrophoresis
technologies, namely the introduction of fluorescent
dyes, which allow multiple samples to be co-separated
and visualized on one 2-D gel, have increased the utility
of this methodology for the discovery of robust protein
biomarkers for disease [18-20]. For example, power anal-
ysis for 2D-DIGE has demonstrated statistical power of
>0.8 for detecting 2-fold changes at p ≤ 0.01 with 4 bio-
logical replicates[21]. In our experiment urine samples
representing 4 control and 4 age matched infected cattle
were run with an internal standard. The internal standard,
created by pooling aliquots of all biological samples in
the experiment, was run on all gels within the experiment
thereby creating an intrinsic link across all gels. Normali-
zation of the internal standard across gels allowed the
ratio of relative abundance of the same protein to be com-
pared directly, separating gel-to-gel variation from biolog-
ical variation. Differences in protein abundance were then
determined by comparing the ratio obtained from one
fluorescent labelled sample directly with another.
Changes in the amount of a given soluble protein in urine
can result from a change in its concentration in the blood
plasma, a change in the function of the glomerular filter,
an alteration in the proximal tubule scavenging system or
a change in local production and excretion[22]. No pro-
teinuria indicating a change in the glomerular filter was
Table 2: Classification Matrix
83.33% ± 18.3 Class Prediction
control infected normal
control 20 03
infected 0 14 0
normal 0 0 3
no class 0 0 0
error 0 0 3
The classifier created was applied to the training set to assign gel 
maps with respect to disease state. The classification matrix shows an 
overview of the classification of the gel maps. Gels that were 
correctly classified are displayed in bold type. A classifier containing 
16 biomarkers was used to discriminate between the 3 groups with 
83.33% ± 18.3 accuracy. A single protein was able to discriminate 
between control and infected samples with 100% accuracy.
Table 3: Disease Progression Matrix
85% ± 13.2 Infected Progression
08 mpi 16 mpi 24 mpi 32 mpi 40 mpi
08 mpi 3 0000
16 mpi 0 3 000
24 mpi 0 0 2 20
32 mpi 0 0 0 1 0
40 mpi 0 0 0 0 3
n o  c l a s s 00000
error 0 0 0 2 0
The classifier created was applied to the training set to assign gel 
maps with respect to disease progression. The classification matrix 
shows an overview of the classification of the gel maps. Gels that 
were correctly classified are displayed in bold type. A classifier 
containing 16 biomarkers was used to discriminate between the 5 
time points with 85% ± 13.2 accuracy. The two misclassified samples 
at 32 mpi were placed into the immediately proceeding sampling time.
Table 4: Aging Matrix
85% ± 19.1 Control Progression
08 mpi 16 mpi 24 mpi 32 mpi 40 mpi
08 mpi 4 1000
16 mpi 0 3 110
24 mpi 0 0 3 00
32 mpi 0 0 0 3 0
40 mpi 0 0 0 0 4
no class 0 0 0 0 0
error 0 1 1 1 0
The classifier created was applied to the training set to assign gel 
maps with respect to sample collection time. The classification matrix 
shows an overview of the classification of the gel maps. Gels that 
were correctly classified are displayed in bold type. A classifier 
containing 16 biomarkers was used to discriminate between the 5 
time points with 85% ± 19.2 accuracy. The misclassified samples at 16 
and 24 mpi were placed into the immediately proceeding sampling 
times. The misclassified sample at 32 mpi was classified as 16 mpi.Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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observed in response to BSE infection (Additional file 2).
In addition, no significant difference (p < 0.01) in the
standardized log of abundance for cystatin was observed
at any time point when compared to the corresponding
control (Additional file 3). Cystatin is a low molecular
weight cysteine proteinase inhibitor that is freely filtered
by the renal glomeruli and reabsorbed in the proximal
tubules. Consequently cystatin serves as an indicator of
the health of the proximal tubule scavenging sys-
tem[23,24]. The absence of change in cystatin abundance
indicated that the proximal tubule scavenging system was
unaffected by BSE infection. Together these results suggest
that the differential abundances observed in response to
BSE infection were likely due to changes in the protein
concentration in the blood plasma or a disease associated
alteration in local production.
One of the identified classifier proteins that exhibited
increased abundance in response to infection was immu-
noglobulin Gamma-2 chain C region. Increased immu-
noglobulin has previously been observed in the urine of
scrapie infected hamsters and in one report it was specu-
lated that this was the result of a nephritic syndrome
[5,6,16]. In contrast, the data presented suggests that the
increased abundance of immunoglobulin in urine associ-
Proteins that exhibited a steady increase or decrease in abundance throughout disease progression Figure 5
Proteins that exhibited a steady increase or decrease in abundance throughout disease progression. The average 
standardized abundance ratios of the top three ranked proteins used in the disease progression classier (437, 1041, 1022) are 
shown. The consistent increase or decrease in abundance over the course of the experiment illustrates the utility of the rela-
tive abundance of these spot features in classifying the urine samples with respect to date post infection.
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Table 5: Biomarker sets used to create classifiers.
Control Progression Disease Progression Class Prediction
Spot # Rank Spot # Rank Spot # Rank
1 161 10 125 9 387 2
2 168 8 127 6 393 3
3 395 2 239 4 405 1
4 473 6 297 10 597 11
5 482 6 437 1 749 12
6 603 3 597 58 9 6 1 0
7 608 5 626 6 1022 8
8 710 8 710 11 1038 7
9 860 10 740 8 1041 12
10 1006 10 841 9 1043 4
11 1007 4 911 7 1071 12
12 1101 7 1022 31 1 2 3 9
13 1127 9 1041 21 1 2 4 5
14 1200 1 1078 12 1150 10
15 1278 4 1103 11 1198 8
16 1457 9 1318 10 1228 6
In this particular instance each classifier was composed of 16 
biomarkers. Biomarkers that appear in more than one classifier are in 
italics. The three biomarkers in the class prediction set that were not 
identified by MS analysis (387,1041,1150) are in bold faced type.Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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ated with BSE was probably due to a change in immu-
noglobulin concentration in the blood plasma.
Nonetheless, the detection of differential abundance of
another immunoglobulin protein in urine by an unbiased
screen lends support to the suggestion that immunoglob-
ulin light chain may constitute a surrogate marker for TSE
diseases[6,16].
In addition to immunoglobulin Gamma-2 chain C region
and cystatin, the 3 other identified classifier proteins were
well known urinary proteins. One was the antimicrobial
peptide cathelicidin that is produced in the kidney by the
epithelial cells that line the urinary tract. When exposed to
bacteria the levels of cathelcidin mRNA are known to rap-
idly increase, however, even in the absence of microbes
the epithelial surface of the urinary tract are continuously
bathed with cathelicidin[25,26]. A second protein was the
natriuretic peptide uroguanylin that is produced in the
small intestine and kidney. In response to salt loading no
increase in circulating uroguanylin is observed indicating
that the natriuretic effect of uroguanylin is in part medi-
ated by increased renal production that inhibits tubular
resorption of ions from the glomerular filtrate[27]. These
characteristics suggested that the decreased abundance of
both cathelicidin, observed after 24 mpi, and uroguanylin
throughout the experiment were probably the result of
decreased renal production and excretion. The precise
cause of the decreased production and the possible effects
of the altered abundance on prion pathobiology are not
known.
The third protein, identified as clusterin, was able to dis-
tinguish between infected animals and age matched con-
trols with 100% accuracy throughout the experiment.
Clusterin is a multifunctional glycoprotein with nearly
ubiquitous tissue distribution[28]. Increased abundance
of clusterin in association with TSE diseases has been
reported previously and has included increased expres-
sion in astrocytes as well as a significant accumulation in
cerebrospinal fluid and blood plasma[29]. Thus,
increased amounts of circulating clusterin may have
caused the increased clusterin abundance observed in the
urine of the BSE infected animals. Despite the power of
clusterin as a biomarker of BSE in this experiment, the
increased clusterin abundance in CSF observed in models
of other neurodegenerative diseases, such as Alzheimer's
disease, and in response to a variety of renal insults raises
doubts as to the specificity of clusterin per se as a biomar-
ker of BSE in cattle [30-34]. However, the specificity of the
particular isoform of clusterin observed to best discrimi-
nate between BSE infected and control cattle remains to
be seen.
EDA analyses also demonstrated that the differential
abundance of different subsets of proteins provided accu-
rate measures of disease progression and aging. This was
an unexpected result, but the ability to follow disease pro-
gression by monitoring the differential abundance of a
subset of proteins has potential applications as a prognos-
tic indicator or in the assessment of the therapeutic bene-
fit of potential treatments. Furthermore, while markers of
disease progression must be sensitive to changes in dis-
ease state and present in easily accessible tissues that per-
mit repeated sampling, they do not require the same high
disease specificity as diagnostic markers. The ultimate util-
ity of these markers of disease progression will be deter-
Table 6: Thirteen of the 16 spot features included in the class prediction classifier were identified. The average ratios at each time 
point are given.
Average Ratio (infected/control)
Spot Protein ID 0 mpi 8 mpi 16 mpi 24 mpi 32 mpi 40 mpi
387 2.04 12.35 10.91 7.63 2.46 8.70
393 clusterin (Bos Taurus) 2.44 11.36 9.17 5.23 10.12 6.76
405 clusterin (Bos Taurus) 4.05 23.68 77.54 17.00 54.36 33.80
597 Ig Gamma-2 chain C region (Bos taurus) 1.98 -1.4 3.58 2.35 3.03 4.93
749 simlar to GCAP-11/uroguanylin (Bos taurus) -1.33 1.80 1.03 -1.23 1.03 1.15
896 cystatin E/M (Bos Taurus) -1.15 1.13 -1.09 1.23 -1.33 1.10
1022 cathelicidin antimicrobial peptide (Bos Taurus) -1.10 -1.12 -1.02 -2.54 -1.61 -1.91
1038 cathelicidin 1 (Bos Taurus) -3.84 1.03 -1.91 -4.13 -2.46 -1.87
1041 -1.10 -1.17 -1.14 -2.77 -1.80 -2.18
1043 cathelicidin 1 (Bos Taurus) 1.35 1.27 1.13 -2.99 -1.61 -1.60
1071 cathelicidin 1 (Bos Taurus) 1.23 -1.47 -1.20 -2.29 -1.76 -1.81
1123 simlar to GCAP-11/uroguanylin (Bos taurus) 1.35 -1.14 1.05 -2.98 -1.91 -2.51
1124 simlar to GCAP-11/uroguanylin (Bos taurus) 1.27 -3.52 -2.25 -3.19 -2.28 -2.55
1150 1.38 -3.02 -1.66 -1.08 -5.36 1.01
1198 simlar to GCAP-11/uroguanylin (Bos taurus) -1.34 -3.00 -1.49 -1.04 -4.16 -1.43
1228 simlar to GCAP-11/uroguanylin (Bos taurus) -1.11 -5.84 -5.19 -6.95 -3.20 -3.98Proteome Science 2008, 6:23 http://www.proteomesci.com/content/6/1/23
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mined by their identification and validation as well as
their applicability to clinically relevant disease models.
Significantly, the markers of disease progression demon-
strated very little overlap with those identified as able to
track age. This indicates that they were a measure of dis-
ease specific progression and that their identification may
also provide insight into the pathology of these diseases.
The results demonstrate that in principle it is possible to
identify biomarkers of TSE disease by analyzing changes
in the urine protein profile provoked by the disease.
Extending the present study to larger numbers of cattle
and to those of other strains will test the value of the
biomarkers identified. Even more promising markers may
have been missed due to the bias of 2D-DIGE to the iden-
tification of abundant proteins. This shortfall will be
addressed in future studies by utilizing a variety of pre-
fractionation methods.
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